Excedrin Suspends Sale of Popular Migraine Medication
GlaxoSmithKline temporarily suspends production of Excedrin Extra Strength and Excedrin Migraine Capsules
Friday, January 24, 2020 - Pharmaceutical company GlaxoSmithKline has announced that it will temporarily discontinue manufacturing and distribution of two of its Excedrin headache and pain medications. Production and sales of Excedrin Extra Strength and Excedrin Migraine are on hold due to inconsistencies in weighing and dosing active ingredients in the products' caplets and geltabs.
"Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs," GlaxoSmithKline said in a statement issued to NBC News.
Despite statements GlaxoSmithKline reported to multiple news outlets, there is no formal announcement or press release provided at this time on their website, glaxosmithkline.com.
GlaxoSmithKline has said the company has not been made aware of adverse effects resulting from the defective processes, and that the production halt is a precautionary measure.
The active ingredients in Excedrin are caffeine, acetaminophen, and aspirin. Each of these ingredients is available separately in other products. A small cup of coffee is roughly the equivalent of the 65mg of caffeine found in Excedrin. In addition, Excedrin Tension Headache and Excedrin PM Headache are still available.
If you have been using Excedrin Extra Strength and Excedrin Migraine and are unsure what to use while the products are not available, consult your physician.
Using the combination of caffeine, acetaminophen, and aspirin more than two days each week over a period of three months or more has been linked to a condition known as medication overuse headaches, or rebound headaches. Long-term frequent use can also result in liver, kidney, and stomach damage.
OnderLaw, LLC in St. Louis has developed a solid reputation of excellence as a personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. OnderLaw has represented clients throughout the United States in pharmaceutical and medical device litigation, including Pradaxa, Lexapro and Yasmin/Yaz, Actos, Risperdal and others. OnderLaw has won verdicts of more than $300 million in talcum powder ovarian cancer lawsuits and represent more Glyphosate victims than any other firm in the country.